Biomarin Pharmaceutical Inc., of San Rafael, Calif., said its net loss for 2018 decreased $39.8 million, or 34 percent, to $77.2 million, compared to $117 million in 2017. The net loss for the quarter ended Dec. 31 decreased to $3.6 million, compared to a net loss of $51.4 million for same period in 2017.